[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"heart-valve-diseases-or-prosthesis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:heart-valve-diseases-or-prosthesis":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":4},"100612290","comparison-of-early-postoperative-outcomes-between-minimally-invasive-valve-surgery-via-right-thoracotomy-and-conventional-valve-surgery-via-sternotomy-100612290",false,"NCT07251660","Comparison of Early Postoperative Outcomes Between Minimally Invasive Valve Surgery Via Right Thoracotomy and Conventional Valve Surgery Via Sternotomy.","Comparison of Early Postoperative Outcomes Between Minimally Invasive Valve Surgery Via Right Thoracotomy and Conventional Valve Surgery Via Sternotomy","Inclusion Criteria:\n\n* Patients of any age and gender.\n* Undergoing elective, isolated mitral or aortic valve surgery.\n* Considered suitable for either:\n\n  * MIVS via right thoracotomy, or\n  * Conventional valve surgery , as decided by the operating surgical team.\n* Patients giving written informed consent.\n\nExclusion Criteria:\n\n* Emergency or redo cardiac surgeries\n* Concomitant cardiac procedures (e.g., CABG, multiple valve replacements)\n* Ejection Fraction \\\u003C30%\n* Severe pulmonary hypertension (identified as the mean pulmonary artery pressure (mPAP) exceeding 45 mmHg on echocardiography, as outlined by the AHA guidelines(10).\n* Active systemic infections or sepsis at the time of surgery\n* Refusal to participate in the study","ALL",{"count":18,"type":19},32,"ESTIMATED","INTERVENTIONAL",[22],"NA","This randomized controlled trial aims to compare early postoperative outcomes between Minimally Invasive Valve Surgery (MIVS) via right thoracotomy and Conventional Valve Surgery via median sternotomy in patients undergoing elective, isolated mitral or aortic valve surgery. Minimally invasive techniques are believed to reduce postoperative pain, ventilation time, chest drain output, and wound complications, but evidence from Pakistan is limited.\n\nThe study will enroll patients of all ages and genders who are scheduled for isolated valvular procedures at Chaudhary Pervaiz Elahi Institute of Cardiology (CPEIC), Multan. Participants will be randomly assigned to undergo either minimally invasive thoracotomy or conventional sternotomy.\n\nPrimary outcomes include ventilation time, CPB duration, cross-clamp time, pain scores, and chest drain output. Secondary outcomes include wound healing (Day 7 and 30 days), return to routine activity, echocardiographic evaluation, transfusion requirements, and 30-day mortality. Findings from this study may provide evidence to guide the adoption of minimally invasive valvular surgery techniques in low-resource and developing settings.",[25,26,27,28],"Heart Valve Diseases or Prosthesis","Aortic Valve Stenosis","Aortic Valve Insufficiency","Valvular Heart Disease Stenosis and Regurgitation (Diagnosis)",[30,31,32,33,34],"Heart valve disease","Mitral valve surgery Aortic valve surgery Minimally invasive cardiac surgery","Conventional open-heart surgery","Aortic cross-clamping","Early postoperative outcomes","NOT_YET_RECRUITING","2025-11-19",{"date":38,"type":39},"2025-11-26","ACTUAL",{"date":41,"type":19},"2025-12-15",{"date":43,"type":19},"2026-08-15",{"name":45,"class":46},"Chaudhry Pervaiz Elahi Institute of Cardiology","OTHER_GOV",{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":57,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":88},"100226021","start-register-survey-on-anticoagulated-patients-register-100226021","NCT02219984","START-Register: Survey on Anticoagulated Patients Register","Phase 4 Study on Clinical History of Patients Who Start a Chronic Anticoagulant Treatment","Inclusion Criteria:\n\n* age \\>= 18 years\n\nExclusion Criteria:\n\n* \\\u003C 18 years\n* not willing to sign informed consent","18 Years",{"count":56,"type":19},15410,"1 Year","OBSERVATIONAL","This is a phase 4 cohort prospective, open, national, multicentre study that collects data on history of patients treated chronically with anticoagulant drugs, including the novel direct oral anticoagulants (DOACs). The Registry is designed solely for observational purposes and is not intended to have any influence on the treatment of the single patients included.\n\nPatients are included when they start the anticoagulant treatment, whatever the drug used, or when they shift from a vitamin K antagonist (VKA) drug to one of the novel direct oral anticoagulants, provided that the therapy is expected to last at least 3 months.\n\nThe general aims of the study are to provide a better evaluation of efficacy and safety of different treatment options, and to improve our understanding of the risks\u002Fbenefits of the various anticoagulant drugs and the different therapy options.\n\nThe Registry is open to the participation of clinical centres or individual professionals (now called Participants) that are involved with management of anticoagulated patients.",[61,62,25],"Atrial Fibrillation","Venous Thromboembolism",[64,65,66,67,68,69,70,71,72,73,74,75,76],"Anticoagulation","vitamin K antagonists","Warfarin","low molecular weight heparin","fondaparinux","antithrombotics","Direct oral anticoagulants","dabigatran","rivaroxaban","apixaban","edoxaban","atrial fibrillation","venous thromboembolism","RECRUITING","2023-02-01",{"date":80,"type":39},"2023-02-02",{"date":82,"type":39},"2011-10",{"date":84,"type":19},"2027-11",{"name":86,"class":87},"GUALTIERO PALARETI","OTHER",1]